Model-Informed Approach Supporting Approval of Adalimumab (HUMIRA) in Pediatric Patients with Ulcerative Colitis from a Regulatory Perspective
This article provides a case example of successful model-informed drug development (MIDD), where modeling and simulation were utilized in combination with observed data from a clinical trial of limited size and scope to ultimately support the adalimumab approval in p ediatric patients with UC.
Source: The AAPS Journal - Category: Drugs & Pharmacology Source Type: research
More News: Clinical Trials | Drugs & Pharmacology | Eyes | Food and Drug Administration (FDA) | Humira | Inflammatory Bowel Disease | Pediatrics | Study | Ulcerative Colitis